Curis (CRIS) vs Liminatus Pharma (LIMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Liminatus Pharma is the larger company by market cap ($4.9 million vs $1.6 million), about 3.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRIS | LIMN |
|---|---|---|
| Share price | $0.6789 | $3.67 |
| Market cap | $1.65M | $4.93M |
| 1-day change | -4.30% | -0.54% |
| P/E ratio (TTM) | 0.51 | — |
| EPS (TTM) | $1.32 | $-23.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.60 | $141.50 |
| 52-week low | $0.61 | $3.29 |
| Distance from 52-week high | -97.98% | -97.41% |
| Analyst consensus | none | — |
| Avg. price target upside | +6185.17% | — |
| Average volume | 199.15K | 453.28K |
| Shares outstanding | 2.43M | 1.34M |
| Employees | 20 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Liminatus Pharma is about 3.0 times larger than Curis by market value ($4.93M vs $1.65M).
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
CRIS vs LIMN FAQ
Which is bigger, Curis or Liminatus Pharma?
Liminatus Pharma (LIMN) is larger, with a market capitalization of $4.93M compared with $1.65M for Curis (CRIS).
Are Curis and Liminatus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.